FDA decision to restrict ESAs may boost business for Cerus

09/15/2008 | East Bay (Calif.) Business Times

The FDA's decision to restrict the use of erythropoiesis-stimulating agents in cancer patients with anemia likely will boost the number of blood transfusions in the U.S., said Dr. Laurence Corash, chief medical officer of Cerus Corp. The change is expected to increase demand for the company's products, including the Intercept blood-safety system, which has yet to obtain FDA approval.

View Full Article in:

East Bay (Calif.) Business Times

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health